title: Effects of a phenylbutazone paste in ponies: model of acute nonimmune inflammation.
abstract: In a 12-day treatment schedule, 5 ponies were given orally a paste formulation of phenylbutazone (PBZ) and 5 matched ponies were given equivalent doses of a placebo paste. On day 12, a mild, nonimmune inflammatory reaction was induced subcutaneously in the neck of each pony by inserting sterile, polyester sponge strips soaked in a 2% carrageenan solution. Exudate was collected at 4, 8, 12, and 24 hours by serial removal of sponges. There were no significant (P less than 0.05) differences in exudate protein concentration and leukocyte numbers between the treatment groups, but the group given PBZ had significantly reduced exudate concentrations of eicosanoids 6-keto-prostaglandin F 1 alpha (the stable metabolite of prostacyclin) at 4, 8, and 12 hours; thromboxane B2 at 8, 12, and 24 hours; and bicyclic prostaglandin E2 at 8 hours. The maximal depression of eicosanoid synthesis occurred at times of peak exudate concentrations of PBZ (8 and 12 hours). Phenylbutazone was cleared more slowly from exudate than from plasma. Changes in surface skin temperature were measured by infrared thermometry. Lesional temperatures were recorded 1 cm below the base of the incision line, and mean increases were significantly (P less than 0.05) less in PBZ-treated than in placebo-treated ponies between 4 and 24 hours. The importance of the findings for the clinical efficacy of this dosage schedule is considered.
authors.forename: P
authors.initials: P
authors.lastname: Lees
authors.forename: A J
authors.initials: AJ
authors.lastname: Higgins
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000032:analysis; D000818:Animals; D001831:Body Temperature; D015232:Dinoprostone; D004195:Disease Models, Animal; D005122:Exudates and Transudates / Q000032:analysis; D005260:Female; D006734:Horse Diseases / Q000188:drug therapy* / Q000378:metabolism; D006736:Horses; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism / Q000662:veterinary*; D007958:Leukocyte Count / Q000662:veterinary; D008297:Male; D010653:Phenylbutazone / Q000378:metabolism / Q000627:therapeutic use*; D011458:Prostaglandins E / Q000032:analysis; D013929:Thromboxane B2 / Q000032:analysis
chemical_list: D011458:Prostaglandins E; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D010653:Phenylbutazone; D015232:Dinoprostone